[Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000031:analogs & derivatives / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007376:Interleukin-2; D010671:Phenylurea Compounds; D011725:Pyridines; D011994:Recombinant Proteins; D009536:Niacinamide; D000077157:Sorafenib; C082598:aldesleukin